drugset / Trial / NCT06569485
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
NaSingle-groupOpen-labelPrevention
Summary
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
Timeline
- Start
- 2024-05-23
- Primary completion
- 2024-12-30
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | 240 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Epirubicin | Small molecule | 60 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |